Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3000328 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Single dose of placebo administered orally in 1 out of 3 study periods separated by at least a 7-day wash-out period between each dose. |
| LY3000328 | EXPERIMENTAL | Single escalating dose of up to 300 mg/kg of LY3000328 administered orally in 2 out of 3 study periods separated by at least a 7 day wash-out period between each dose. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Administered orally |
| LY3000328 | DRUG | Administered orally |
Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination
LY3000328 is an investigational small molecule being developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy volunteers. The specific disease or condition it is intended to treat has not been disclosed.
LY3000328 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly conducted the Phase 1 study of the compound in healthy participants.
LY3000328 is in Phase 1 development. It has completed one Phase 1 clinical trial, and no later-stage trials have been initiated. It is an investigational drug and has not been approved by the FDA.
LY3000328 has been evaluated in one completed Phase 1 trial, NCT01515358, titled A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants. The trial enrolled 18 healthy volunteers in Singapore and was randomized, double-blind, and placebo-controlled.
The Phase 1 trial NCT01515358 evaluated the safety and tolerability of LY3000328 in healthy participants. It was a randomized, double-blind, placebo-controlled study that enrolled 18 participants in Singapore. Participants were 35 years of age or older, and the trial has been completed.